Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
